JPH0440343B2 - - Google Patents

Info

Publication number
JPH0440343B2
JPH0440343B2 JP2120164A JP12016490A JPH0440343B2 JP H0440343 B2 JPH0440343 B2 JP H0440343B2 JP 2120164 A JP2120164 A JP 2120164A JP 12016490 A JP12016490 A JP 12016490A JP H0440343 B2 JPH0440343 B2 JP H0440343B2
Authority
JP
Japan
Prior art keywords
hydrogen
compound
formula
compounds
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2120164A
Other languages
English (en)
Japanese (ja)
Other versions
JPH0347167A (ja
Inventor
Fuaizura Guramufusein Kasawara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sandoz AG
Original Assignee
Sandoz AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz AG filed Critical Sandoz AG
Publication of JPH0347167A publication Critical patent/JPH0347167A/ja
Publication of JPH0440343B2 publication Critical patent/JPH0440343B2/ja
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2120164A 1982-11-22 1990-05-11 メバロノラクトンの複素環同族体 Granted JPH0347167A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US44366882A 1982-11-22 1982-11-22
US443668 1982-11-22
US54885083A 1983-11-04 1983-11-04
US548850 1983-11-04

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP58503754A Division JPS60500015A (ja) 1982-11-22 1983-11-18 メバロラクトン同族体とその誘導体、これらの製造法およびこれらを含有する製薬学的組成物

Publications (2)

Publication Number Publication Date
JPH0347167A JPH0347167A (ja) 1991-02-28
JPH0440343B2 true JPH0440343B2 (member.php) 1992-07-02

Family

ID=27033614

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2120164A Granted JPH0347167A (ja) 1982-11-22 1990-05-11 メバロノラクトンの複素環同族体

Country Status (18)

Country Link
EP (1) EP0114027B1 (member.php)
JP (1) JPH0347167A (member.php)
AT (1) ATE31718T1 (member.php)
AU (1) AU570021B2 (member.php)
CA (1) CA1210405A (member.php)
CY (1) CY1579A (member.php)
DE (2) DE19475017I2 (member.php)
DK (2) DK359284D0 (member.php)
FI (1) FI77228C (member.php)
GR (1) GR79042B (member.php)
HK (1) HK11191A (member.php)
HU (1) HU204253B (member.php)
IE (1) IE56262B1 (member.php)
IL (1) IL70286A (member.php)
LU (1) LU88670I2 (member.php)
NL (1) NL950022I2 (member.php)
NZ (1) NZ206338A (member.php)
WO (1) WO1984002131A1 (member.php)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5354772A (en) * 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4613610A (en) * 1984-06-22 1986-09-23 Sandoz Pharmaceuticals Corp. Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives
US5001255A (en) * 1984-12-04 1991-03-19 Sandoz Pharm. Corp. Idene analogs of mevalonolactone and derivatives thereof
DE3581638D1 (de) * 1984-12-04 1991-03-07 Sandoz Ag Inden-analoga von mevalonolakton und ihre derivate.
US4668794A (en) * 1985-05-22 1987-05-26 Sandoz Pharm. Corp. Intermediate imidazole acrolein analogs
EP0221025A1 (en) * 1985-10-25 1987-05-06 Sandoz Ag Heterocyclic analogs of mevalonolactone and derivatives thereof, processes for their production and their use as pharmaceuticals
US4851427A (en) * 1985-10-25 1989-07-25 Sandoz Pharm. Corp. Pyrrole analogs of mevalonolactone, derivatives thereof and pharmaceutical use
US4751235A (en) * 1986-12-23 1988-06-14 Sandoz Pharm. Corp. Anti-atherosclerotic indolizine derivatives
PT85662B (pt) * 1986-09-10 1990-06-29 Sandoz Sa Processo para a preparacao de derivados de aza-indol e de indolizina e de composicoes farmaceuticas que os contem
US4735958A (en) * 1986-12-22 1988-04-05 Warner-Lambert Company Trans-6-[2-[2-(substituted-phenyl)-3- (or 4-) heteroaryl-5-substituted-1H-pyrrol-1-yl]-ethyl]tetrahydro-4-hydroxy-2H-pyran-2-one inhibitors of cholesterol biosynthesis
US4897490A (en) * 1987-02-25 1990-01-30 Bristol-Meyers Company Antihypercholesterolemic tetrazole compounds
US4898949A (en) * 1987-02-25 1990-02-06 Bristol-Myers Company Intermediates for the preparation of antihypercholesterolemic tetrazole compounds
US4894386A (en) * 1987-04-15 1990-01-16 Ici Americas Inc. Aliphatic carboxamides
US4904646A (en) * 1987-05-22 1990-02-27 E. R. Squibb & Sons, Inc. Phosphorus-containing HMG-COA reductase inhibitors
US5091378A (en) * 1987-05-22 1992-02-25 E. R. Squibb & Sons, Inc. Phosphorus-containing HMG-CoA reductase inhibitors, new intermediates and method
CA1336714C (en) * 1987-08-20 1995-08-15 Yoshihiro Fujikawa Quinoline type mevalonolactone inhibitors of cholesterol biosynthesis
US5185328A (en) * 1987-08-20 1993-02-09 Nissan Chemical Industries Ltd. Quinoline type mevalonolactones useful for treating hyperlipidemia, hyperlipoproteinemia or atherosclerosis
JP2569746B2 (ja) * 1987-08-20 1997-01-08 日産化学工業株式会社 キノリン系メバロノラクトン類
DE3739882A1 (de) * 1987-11-25 1989-06-08 Bayer Ag Substituierte hydroxylamine
US4868185A (en) * 1987-12-10 1989-09-19 Warner-Lambert Company 6-[[Substituted)pyrimidinyl)ethyl]- and ethenyl]tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
JPH01242570A (ja) * 1988-01-27 1989-09-27 May & Baker Ltd イソキノリノン類
US4822799A (en) * 1988-01-27 1989-04-18 Sandoz Pharm. Corp. Pyrazolopyridine analogs of mevalonolactone and derivatives thereof useful for inhibiting cholesterol biosynthesis in mammals
NO890522L (no) * 1988-02-25 1989-08-28 Bayer Ag Substituerte imidazolinoner og imidazolinthioner.
US5024999A (en) * 1988-04-26 1991-06-18 Nissan Chemical Industries Ltd. Pyrazolopyridine type mevalonolactones useful as pharmaeuticals
JP2890448B2 (ja) * 1988-04-26 1999-05-17 日産化学工業株式会社 ピラゾロピリジン系メバロノラクトン類
US5010205A (en) * 1988-08-23 1991-04-23 Bristol-Myers Company Antihypercholesterolemic tetrazol-1-yl intermediates
US4870187A (en) * 1988-08-23 1989-09-26 Bristol-Myers Company Antihypercholesterolemic tetrazol-1-yl compounds
US5506219A (en) * 1988-08-29 1996-04-09 E. R. Squibb & Sons, Inc. Pyridine anchors for HMG-CoA reductase inhibitors
NZ230121A (en) * 1988-08-29 1993-08-26 Squibb & Sons Inc Pyridine and quinoline terminal groups for hmg-coenzyme a reductase inhibitors and pharmaceutical compositions for lowering blood serum cholesterol levels
YU48466B (sh) * 1988-10-13 1998-08-14 Novartis Ag. Postupak za dobijanje 7-supstituisanih-hept-6-enskih i heptanskih kiselina i njihovih derivata
JPH04270285A (ja) * 1988-11-14 1992-09-25 Nissan Chem Ind Ltd ピラゾロピリミジン系メバロノラクトン類
DE3911064A1 (de) * 1989-04-06 1990-10-11 Bayer Ag Substituierte 1,8-naphthyridine
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
GB8919091D0 (en) * 1989-08-22 1989-10-04 Fujisawa Pharmaceutical Co Pyrroloquinoline compounds
IT1237792B (it) * 1989-12-21 1993-06-17 Zambon Spa Composti attivi come inibitori dell'enzima hmg-coa reduttasi
HU9203780D0 (en) * 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
DE4243279A1 (de) 1992-12-21 1994-06-23 Bayer Ag Substituierte Triole
JP2736599B2 (ja) * 1993-07-23 1998-04-02 株式会社キッツ ボールバルブのシート構造
DE19513716A1 (de) * 1995-02-01 1996-08-08 Bayer Ag Substituierte 2-Phenylindol-Derivate
US6425881B1 (en) 1994-10-05 2002-07-30 Nitrosystems, Inc. Therapeutic mixture useful in inhibiting lesion formation after vascular injury
JP4282092B2 (ja) * 1996-06-24 2009-06-17 ノバルティス アクチエンゲゼルシャフト 多形性化合物
EP0988289A2 (en) 1997-06-05 2000-03-29 Takeda Pharmaceutical Company Limited Heterocyclic compounds, their production and use
HUP0105089A3 (en) 1998-11-20 2002-09-30 Skyepharma Canada Inc Compositions containing the active ingredient in form dispersible phospholipid stabilized microparticles
US6242003B1 (en) 2000-04-13 2001-06-05 Novartis Ag Organic compounds
CN1217930C (zh) 2000-05-26 2005-09-07 西巴特殊化学品控股有限公司 吲哚衍生物的制备方法和该方法的中间体
US20060127474A1 (en) 2001-04-11 2006-06-15 Oskar Kalb Pharmaceutical compositions comprising fluvastatin
EP2172204A1 (en) 2001-04-18 2010-04-07 Genzyme Corporation Methods of treating syndrome X with apliphatic polyamines
IL159861A0 (en) * 2001-08-03 2004-06-20 Ciba Sc Holding Ag Crystalline forms of fluvastatin sodium
EP1465882B1 (en) 2001-12-21 2011-08-24 X-Ceptor Therapeutics, Inc. Hetrocyclic modulators of nuclear receptors
CA2480879A1 (en) 2002-04-12 2003-10-23 Merck & Co., Inc. Tyrosine kinase inhibitors
CA2535359A1 (en) 2003-08-21 2005-03-03 Merck Frosst Canada Ltd. Cathepsin cysteine protease inhibitors
EP1510208A1 (en) 2003-08-22 2005-03-02 Fournier Laboratories Ireland Limited Pharmaceutical composition comprising a combination of metformin and statin
CN100404479C (zh) * 2003-08-27 2008-07-23 住友化学株式会社 芳族不饱和化合物的制备方法
US8227434B1 (en) 2003-11-04 2012-07-24 H. Lee Moffitt Cancer Center & Research Institute, Inc. Materials and methods for treating oncological disorders
US7709508B2 (en) 2004-12-09 2010-05-04 Merck Sharp & Dohme Estrogen receptor modulators
KR20070085874A (ko) * 2004-12-09 2007-08-27 머크 앤드 캄파니 인코포레이티드 에스트로겐 수용체 조절제
AU2006302797B2 (en) 2005-03-02 2012-02-02 Merck Canada Inc. Composition for inhibition of cathepsin K
CA2613517A1 (en) 2005-06-27 2007-01-04 Exelixis, Inc. Pyrazole based lxr modulators
WO2007017117A1 (en) * 2005-07-28 2007-02-15 Lek Pharmaceuticals D.D. Process for the synthesis of rosuvastatin calcium
TWI387592B (zh) 2005-08-30 2013-03-01 Novartis Ag 經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法
US8440695B2 (en) 2005-11-09 2013-05-14 St Jude Children's Research Hospital Use of chloroquine to treat metabolic syndrome
HUE035654T2 (en) 2006-04-19 2018-05-28 Novartis Ag 6-o-substituted benzoxazole and benzothiazole compounds and methods for inhibiting CSF-1R signaling
DE602006006899D1 (de) 2006-04-20 2009-07-02 Italiana Sint Spa Verfahren zur Herstellung von Fluvastatin-Natrium
EP2359826B1 (en) 2006-07-05 2013-10-30 Takeda GmbH Combination of HMG-COA reductase inhibitor rosuvastatin with a phosphodiesterase 4 inhibitor, such as roflumilast, roflumilast-N-oxide for the treatment of inflammatory pulmonary diseases
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
CN101679266B (zh) 2007-03-01 2015-05-06 诺华股份有限公司 Pim激酶抑制剂及其应用方法
ES2452349T3 (es) 2007-05-21 2014-04-01 Novartis Ag Inhibidores de CSF-1R, composiciones, y métodos de uso
ES2330184B1 (es) 2008-06-03 2010-07-05 Neuron Biopharma, S.A. Uso de estatinas como anticonvulsivantes, antiepilepticos y neuroprotectores.
EP2327682A1 (en) 2009-10-29 2011-06-01 KRKA, D.D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
WO2010069593A1 (en) 2008-12-19 2010-06-24 Krka, D. D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
AU2010254082B2 (en) 2009-05-28 2015-01-29 Exelixis, Inc. LXR modulators
CN102480966B (zh) 2009-06-12 2015-09-16 达娜-法勃肿瘤研究所公司 融合的杂环化合物及其用途
US9180127B2 (en) 2009-12-29 2015-11-10 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
US8987275B2 (en) 2010-03-16 2015-03-24 Dana-Farber Cancer Institute, Inc. Indazole compounds and their uses
US8372877B2 (en) 2010-04-16 2013-02-12 Cumberland Pharmaceuticals Stabilized statin formulations
WO2012046772A1 (ja) 2010-10-06 2012-04-12 国立大学法人東京大学 リンパ浮腫予防治療剤
EP2675440B1 (en) 2011-02-14 2020-03-25 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
AR088728A1 (es) 2011-03-25 2014-07-02 Bristol Myers Squibb Co Moduladores de lxr como prodroga de imidazol
US9382239B2 (en) 2011-11-17 2016-07-05 Dana-Farber Cancer Institute, Inc. Inhibitors of c-Jun-N-terminal kinase (JNK)
BR112014016154A8 (pt) 2011-12-29 2017-07-04 Tufts College funcionalização de biomateriais para controlar respostas à regeneração e inflamação
US10112927B2 (en) 2012-10-18 2018-10-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
US9758522B2 (en) 2012-10-19 2017-09-12 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
CN105209039B (zh) 2013-03-15 2018-06-22 百时美施贵宝公司 Lxr调节剂
EP2810644A1 (en) 2013-06-06 2014-12-10 Ferrer Internacional, S.A. Oral formulation for the treatment of cardiovascular diseases
JP6454335B2 (ja) 2013-10-08 2019-01-16 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． カテプシンシステインプロテアーゼ阻害剤
WO2015051479A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
CN105849099B (zh) 2013-10-18 2020-01-17 达纳-法伯癌症研究所股份有限公司 周期蛋白依赖性激酶7(cdk7)的多环抑制剂
EP3057955B1 (en) 2013-10-18 2018-04-11 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of prolferative diseases
WO2015120580A1 (en) 2014-02-11 2015-08-20 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
US9862688B2 (en) 2014-04-23 2018-01-09 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
US10017477B2 (en) 2014-04-23 2018-07-10 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
WO2016105528A2 (en) 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
CA2978518C (en) 2015-03-27 2023-11-21 Nathanael S. Gray Inhibitors of cyclin-dependent kinases
WO2016201370A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
WO2017044858A2 (en) 2015-09-09 2017-03-16 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
CN112367991A (zh) 2018-06-25 2021-02-12 达纳-法伯癌症研究所股份有限公司 Taire家族激酶抑制剂及其用途
WO2020140098A1 (en) 2018-12-28 2020-07-02 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 and uses thereof

Also Published As

Publication number Publication date
IE56262B1 (en) 1991-06-05
JPH0347167A (ja) 1991-02-28
DK359284A (da) 1984-07-20
FI842615A7 (fi) 1984-06-28
DE19475017I2 (de) 2003-02-20
AU2261283A (en) 1984-06-18
IL70286A0 (en) 1984-02-29
CA1210405A (en) 1986-08-26
DE3375137D1 (en) 1988-02-11
ATE31718T1 (de) 1988-01-15
HK11191A (en) 1991-02-13
NL950022I1 (member.php) 1996-01-02
FI77228B (fi) 1988-10-31
CY1579A (en) 1991-12-20
HU204253B (en) 1991-12-30
WO1984002131A1 (fr) 1984-06-07
FI842615A0 (fi) 1984-06-28
LU88670I2 (fr) 1996-04-29
FI77228C (fi) 1989-02-10
HUT35642A (en) 1985-07-29
EP0114027A1 (en) 1984-07-25
DK359284D0 (da) 1984-07-20
NL950022I2 (nl) 1996-12-02
NZ206338A (en) 1987-08-31
AU570021B2 (en) 1988-03-03
DK165244B (da) 1992-10-26
DK97890D0 (da) 1990-04-19
DK165244C (da) 1993-03-22
IL70286A (en) 1987-08-31
DK97890A (da) 1990-04-19
EP0114027B1 (en) 1988-01-07
GR79042B (member.php) 1984-10-02
IE832713L (en) 1984-05-22

Similar Documents

Publication Publication Date Title
JPH0440343B2 (member.php)
US4739073A (en) Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
EP0216785B1 (en) Indene analogs of mevalonolactone and derivatives thereof
US4996234A (en) HMG-CoA reductase inhibitors
US5001128A (en) HMG-COA reductase inhibitors
EP0235164B1 (en) Imidazole analogs of mevalonolactone and derivatives thereof
US4686237A (en) Erythro-(E)-7-[3'-C1-3 alkyl-1'-(3",5"-dimethylphenyl)naphth-2'-yl]-3,5-dihydroxyhept-6-enoic acids and derivatives thereof
AU573368B2 (en) Pyrazole analogs of mevalonolactone and derivatives thereof, process for their production and their use
US4863957A (en) Novel HMG-CoA reductase inhibitors
US4946860A (en) Benzothiopyranyl derivatives as HMG-CoA reductase inhibitors
US4994494A (en) HMG-COA reductase inhibitors
EP0117228B1 (en) Analogs of mevalonolactone and derivatives thereof, processes for their production, pharmaceutical compositions containing them and their use as pharmaceuticals
KR900009006B1 (ko) 메발로락톤의 동족체 및 그것의 유도체의 제조방법
EP0367895A1 (en) Pyrimidinyl-substituted hydroxyacids, lactones and esters and pharmaceutical compositions containing them
US5093363A (en) 2,4,6-substituted phenol derivatives
US4870187A (en) Antihypercholesterolemic tetrazol-1-yl compounds
US4892884A (en) Novel hmg-coa reductase inhibitors
US4804679A (en) Erythro-(E)-7-(3'-C1-3alkyl-1'-(3",5"-dimethylphenyl)naphth-2'-yl)-3,5-dihydroxyhept-6-enoic acids and derivatives thereof
US4904691A (en) Novel HMG-CoA reductase inhibitors
US4904692A (en) Novel HMG-CoA reductase inhibitors
US5010205A (en) Antihypercholesterolemic tetrazol-1-yl intermediates
US5070206A (en) Tetrazol-1-yl containing intermediates